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When modern medicine fails, it is often useful to draw ideas
from ancient treatments. The therapeutic use of fly larvae to
debride necrotic tissue, also known as larval therapy, maggot
debridement therapy or biosurgery, dates back to the
beginnings of civilisation. Despite repeatedly falling out of
favour largely because of patient intolerance to the treatment,
the practice of larval therapy is increasing around the world
because of its efficacy, safety and simplicity. Clinical indications
for larval treatment are varied, but, in particular, are wounds
infected with multidrug-resistant bacteria and the presence of
significant co-morbidities precluding surgical intervention. The
flies most often used in larval therapy are the facultative
calliphorids, with the greenbottle blowfly (Lucilia sericata) being
the most widely used species. This review summarises the
fascinating and turbulent history of larval therapy from its origin
to the present day, including mechanisms of action and
evidence for its clinical applications. It also explores future
research directions.
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I
n the twenty first century, when modern
medicine fails, it is often useful to draw ideas
from ancient treatments. The therapeutic use of
fly larvae to debride necrotic tissue, also known as
larval therapy,1 maggot debridement therapy2 or
biosurgery,3 dates back to the beginnings of
civilisation. Despite repeatedly falling out of favour
and the persistent public disdain which hampers
its acceptance, the practice of larval therapy is
increasing around the world because of its efficacy,
safety and simplicity.4 The flies most often used in
larval therapy are the facultative calliphorids, with
the greenbottle blowfly (Lucilia sericata) being the
most widely used species.5 Clinical indications for
larval treatment include infected or necrotic
wounds of all types. Candidates for the treatment
generally have non-acute external wounds for
which one or more courses of alternative treat-
ments have failed.
HISTORY OF LARVAL THERAPY
‘My body is clothed with worms and scabs, my
skin is broken and festering…’
The Holy Bible, Old Testament, Job 7:5.
Larval association with infected wounds has been
reported since ancient times, with the Old
Testament being the oldest written piece to cite
the infestation of an infected wound of a man by
fly larvae (myiasis).6
Evidence exists that larvae have been used for
the last thousand years by various ancient cul-
tures, such as the aboriginal Ngemba tribe of New
South Wales,7 the Hill people of Northern Myanma
(Burma)8 and the Mayan healers of Central
America.9 Anthropological research suggests that
the Maya soaked dressings in the blood of cattle
and exposed them to the sun before applying them
to certain lesions, expecting the dressings to
squirm with maggots.7
The French surgeon, Ambroise Pare (1510–
1590), was the first doctor to note the beneficial
effect of fly larvae for wounds. His early descrip-
tions, however, emphasised the destructive nature
of the maggot, and he conscientiously tried to
protect the wounds of his patients from infesta-
tion.10 11 The turning point came when he observed
a case of a deep wound that had penetrated a
patient’s skull. A number of months after the
injury, a large number of maggots emerged from
the wound. Although a piece of bone the size of a
hand was lost, the patient nevertheless recovered.10
After this, Pare would allow maggots to continue
to survive in wounds for extended periods in an
attempt to facilitate recovery.10
Another French surgeon, Baron Dominique-
Jean Larrey (1766–1842), who treated the injured
of Napoleon’s army, observed that during the
Egyptian expedition in Syria, maggots of the ‘‘blue
fly’’ only removed dead tissue and had a positive
effect on the remaining healthy tissue.12 Larrey’s
written observations clearly described the role of
fly larvae in wound cleaning.8
The first officially documented application of
maggots was performed by John Forney Zacharias
(1837–1901), a surgeon from Maryland during the
American civil war (1861–1865):
‘‘During my service in the hospital at Danville,
Virginia, I first used maggots to remove the
decayed tissue in hospital gangrene and with
eminent satisfaction. In a single day, they
would clean a wound much better than any
agents we had at our command. I used them
afterwards at various places. I am sure I saved
many lives by their use, escaped septicaemia,
and had rapid recoveries.’’13
William Williams Keen (1837–1932), who was a
surgeon of the army of the North States, also
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reported the presence of fly larvae in wounds and noticed that,
despite their sickness-inducing appearance, they had no
disadvantageous effect.14
At this time, popular scientific belief was that maggots were
‘‘dirty’’ and introduced infections to wounds. The germ theory
of the microbiologists, Robert Koch and Louis Pasteur, during
the second half of the 19th century finally stopped any
willingness of doctors to apply contaminated matter to an
open wound. By the end of the 19th century, there were hardly
any doctors left who would support the use of non-sterile fly
larvae for the public.
During World War I, mortality from open wounds increased
to 70%.15 The available antiseptic tools were often not sufficient.
In 1917, William S Baer, a military surgeon in France, reported
his treatment of open fractures and stomach wounds with
maggots. In 1929, during his appointment as Professor of
Orthopaedic Surgery at the Johns Hopkins University, Baer
recalled and utilised his experiences during the war.15 He chose
21 patients with failed primary treatment for osteomyelitis. He
exposed the wounds to maggots and found that, 2 months after
the initiation of treatment, all of the patients’ wounds had
healed.15
Larval therapy was subsequently the fastest and most
successful mode of treatment for chronic osteomyelitis. To
minimise the disgust of patients, as well as staff, and to avoid
the migration of larvae, doctors created net-cage bandages to
cover and hide the larvae. To reduce the strong itching effect
that larvae caused on healthy skin, Baer covered the border of
wounds with a special bandage. However, the contamination of
some wounds with Clostridium tetani and Clostridium perfringens
led him to the conclusion that sterile maggots needed to be
applied. Baer worked together with some colleagues to create
specific flies for use in therapy and they developed a number of
different methods to sterilise the eggs.16
A large number of Baer’s colleagues disliked the use of
maggots in wound healing as there was little knowledge of the
mechanism of action. Once Baer died, Stanton Knowlton
Livingston, one of Baer’s students, became the authority in the
field of maggot therapy.17 Livingston was such a strong
advocate that he used an extract as a vaccine for his patients,
who often reacted badly.18
‘‘Maggot therapy’’ experienced a real boom from then on
despite some doubtful experiments. Military doctors north of
Burma during World War II observed the therapeutic applica-
tion of the fly larvae by the local population.19 More than 300
US American hospitals introduced maggots into their pro-
gramme of wound healing between 1930 and 1940, and in this
period more than 100 publications appeared.
Unfortunately for the proponents of maggot therapy, in the
early to mid 1940s the use of sulphonamides was already
widespread. Penicillin was produced industrially from 1944
onwards, and the development of new antiseptics led to a rapid
decline in the use of larval therapy. With the exception of
sporadic publications of hopeless cases where the use of fly
larvae was successful,20 21 the academic interest was lost. The
public showed distain,22 and in 1988 Wainwright brought the
majority opinion to a point:
‘‘…Fortunately maggot therapy is now relegated to a
historical backwater, of interest more for its bizarre nature
than its effect on the course of medical science … a therapy
the demise of which no one is likely to mourn…’’23
At the same time, Craig24 described in the US Army Special
Forces Medical Handbook that the use of fly larvae in military life-
threatening situations was a useful alternative. Here the
treatment of wounds with fly larvae was seen as a last
therapeutic tool only in extreme situations.25
Larval therapy’s renaissance in clinical practice started much
sooner after this particular decline.26 In the USA, Ronald
Sherman and Edward Pechter have been strong advocates of
the technique.4 27 At the beginning of the 1990s, Sherman
established a small fly-culturing facility in the Veteran
Administration Hospital Medical Centre in Long Beach
(California) to meet the need for the production of sterile
larvae. In prospective controlled studies during the 1990s,
maggot therapy was compared with conventional therapies in
the treatment of wounds in patients with decubitus ulcers.2
Maggot therapy led to a more rapid removal of debris than all
other non-surgical treatments, and had a faster healing rate. In
necrotic wounds with an average surface area of 13 cm2 (5–
30 cm2), the healing rate was about 1.5 weeks on average, as
assessed by the successful removal of debris, in comparison
with 4 weeks for conventional methods.2 Wounds that were
increasing by 22% surface area per week before treatment with
larvae reduced their area on average by 20% per week after its
use. Furthermore, Sherman28 experimented with different
bandages in order to ensure optimal controlled clinical use of
maggot therapy.
The renaissance of larval therapy in the United Kingdom can
be attributed to John Church, a retired orthopaedic surgeon
who, with Stephen Thomas, set up the Biosurgical Research
Unit in Bridgend, South Wales. Since 1995, the unit has
commercially distributed sterile larvae.4 German and Belgian
factories have distributed fly larvae in middle Europe since
1998. Since 1996, an annual world meeting on larval therapy, or
biosurgery as it was then being called, has taken place. This
meeting is called the International Conference on Biotherapy,
organised by the International Biotherapy Society (IBS).
MECHANISMS OF ACTION
Most flies that facilitate myiasis belong to one of three major
families: Oestridae, Sarcophagidae or Calliphoridae. Only a
minority of the approximately 80 000 species have properties
that enable medical use. Larvae of the greenbottle fly, L sericata,
are currently used routinely.29 The beneficial properties of this
Box 1: Milestones in the history of larval therapy
N The French surgeon Ambroise Pare (1510–1590) notes
the beneficial effect of maggots
N The American Surgeon Forney Zacharias (1837–1901)
officially documents their use during the American Civil
War (1861–1865)
N In 1929, William Baer reports a case series of
osteomyelitis treated with larval therapy based on his
observations during World War I
N Ronald Sherman and Edward Pechter rediscover and
promote the use of larval therapy in the USA in the 1990s
Box 2: Mechanisms of action
N Production of natural antibiotic-like agents
N Alkalinisation of wounds with secreted ammonia, inhibit-
ing bacterial growth
N Injection of microorganisms
N Production of substances to induce wound healing
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subtype of maggot include: exclusive feeding on necrotic
tissues, congregation in vivo, and ability to breed and sterilise
in vitro.1 The key morphological features of medically important
flies have been described by Lane and Crosskey.30 The
mechanisms by which larvae kill bacteria in wounds are not
fully understood, but include the production of natural
antibiotic-like agents,31 the modification of wound pH, and
the ingestion and destruction of bacteria as part of normal
feeding processes. Growth-promoting agents have also been
detected in larval secretions,32 a finding that is consistent with
the clinical observation that the introduction of larvae often
causes a previously indolent wound to heal rapidly.
In order to debride necrotic tissue, larvae produce a mixture
of proteolytic enzymes, including collagenase, which break
down the necrotic tissue to a semi-liquid form, which can then
be absorbed and digested.33 Debridement is facilitated by
wound disturbance as the larvae crawl around the tissue using
their mouthhooks.34 Their antibacterial properties are designed
for self-defence; it is believed that they ingest microorganisms,
which are then destroyed in their gut.32 There is evidence that
they secrete chemicals with a broad-spectrum bactericidal
effect. They also secrete ammonia, causing wounds to become
more alkaline, which is believed to inhibit bacterial growth.
Further studies of the screwworm suggest that phenylacetic
acid and phenylacetaldehyde produced by Proteus mirabilis, a
commensal of the larval gut, may contribute to the antibacterial
effect of larvae.35 36 In vitro, live maggots kill or inhibit the
growth of a range of pathogenic bacteria, especially
Staphylococcus aureus and Group A and B streptococci. They
show some activity against Pseudomonas species but none
against Escherichia coli or Proteus spp.37 Several substances
secreted by maggots have been found to stimulate wound
healing, with larval secretions inducing fibroblast migration
into the wound space, facilitating tissue regeneration.38 As a
result, maggots eliminate odours and kill malignant tissue,39
producing a clean wound, free from necrotic residues.40
CURRENT APPLICATIONS
Treated wounds decrease by an average of 4.1 cm (p = 0.02)
over a 14-day period with larval therapy when compared with
dressings alone.41 This is accompanied by a reduction of necrotic
tissue by 33% in a 4-week period.41 Exudate, wound odour and
pain scores are all significantly decreased when larval therapy is
compared with conventional dressings.42 Taking into account a
number of clinical criteria, wound scores have been signifi-
cantly improved when larval therapy is compared with
dressings alone (a mean (SD) decrease of 13.5 (1.8) to 6.3
(2.7), p,0.001). Wound healing has also been shown to be
significantly more rapid with the addition of larval therapy.43
There is evidence in the literature of the successful use of
larval therapy for traumatic wounds that fail to heal, such as
pressure ulcers, diabetic ulcers, decubital ulcers, neurovascular
and vascular ulcers,44 45 osteomyelitis,46 florid necrotising
fasciitis,47 postsurgical wound infections, and burns.48 Life-
threatening temporal mastoiditis20 and perineal gangrene21 have
also been treated with maggot therapy after unsuccessful
antibiotic and surgical treatments. It has a role in the palliative
care of certain types of tumour or fungating lesions when
surgical intervention is not possible because of anatomical
location or significant co-morbidity.49 Larval therapy may be
used for infections associated with peripheral vascular disease,
although results are often poor in the late stages.50
The few contraindications to the use of larval therapy
comprise restricted use around wounds with organs or blood
vessels exposed, although they may be used around blood
vessels with careful nursing observation. Caution should be
used around fistulae. There is no evidence that larvae are
affected by any antibiotic, chemotherapy or radiotherapy.51
Some authors advocate the use of larval therapy for the
treatment of Fournier’s gangrene22 and even necrotising
fasciitis,34 but this is not to be advocated unless in conjunction
with aggressive surgical debridement or when there are
overwhelming clinical indications and circumstances preclud-
ing surgical intervention. Larvae have been reported to be a
source of infection in themselves, so caution should be used for
septic patients where their use may confuse the clinical
picture.52
ADMINISTRATION OF LARVAE
To apply larval therapy, a wound-sized hole is cut out of
hydrocolloid dressing, a self-adhesive wafer with an outer
semipermeable membrane. This both protects the skin from
irritation by the maggot’s proteolytic enzymes and forms the
base of the adhesive dressing.
The sterile maggots are then moved from their container on
to a special piece of nylon netting placed on a non-woven swab
to draw away moisture. The netting is then ‘‘bunched up’’ to
create a cage for the larvae, which is then placed on the wound.
This is stuck to the hydrocolloid dressing by waterproof
adhesive tape. The dressing is finally covered with a simple
absorbent pad held in place with adhesive tape or a bandage.
FUTURE APPLICATIONS
As public acceptance and medical awareness of larval therapy
increases,51 53 it may be more widely used for superficial
infection in the future. Early application should be considered
to clean up a problematic or infected wound, which in many
cases would obviate the need for topical or systemic anti-
microbial treatment.4 In the face of ever increasing antibiotic
resistance, chronic infections, immunosuppressive illnesses and
diabetes, larval therapy may even become first line treatment
for some infections, although it has stiff competition from
novel techniques such as tissue engineering54 and modern
wound dressings such as vacuum therapy.55 Early clinical
experience suggests that it could be a formidable weapon
against difficult cases of methicillin-resistant S aureus.37 56 57
Many current uses of larval therapy remain improperly
assessed. Randomised trials for the efficacy of larval therapy are
scarce, and there is a need to define acceptable criteria for
clinical outcomes and guidelines for best practice before
carrying them out.5 The ongoing VenUS II trial will begin to
Box 3: Applications of larval therapy
N Any superficial wound excluding those with organs or
blood vessels exposed
N Aggressive superficial infection in conjunction with
surgical debridement and antibiotics
N Some types of fungating cancers
Box 4: Future directions
N Multidrug-resistant infections
N Early, community based application
N Prospective, randomised control trials
N Elucidation of exact mechanisms of action and applica-




provide answers to these questions.58 Infected limbs with
peripheral vascular disease often receive larval treatment as a
last resort, when conventional treatments, including repeated
courses of antibiotics, have failed. Early aggressive surgical
debridement with intravenous antibiotics and larval therapy in
combination may be more effective than these treatments
alone. There is very little published work on maggot therapy for
non-healing infected burns and tumours, where surgical
intervention is contraindicated. Prospective, randomised con-
trolled trials in these areas are indicated. Such trials would
most likely need collaboration between multiple units to
facilitate patient numbers and a suitable study power.
The biosurgical research unit in Wales produces sterilised
eggs which have been raised through bacteria-free adult flies. If
this can be scaled up, it will eliminate the need for time-
consuming sterilisation procedures. Laboratory studies are
underway to isolate and identify enzyme systems and
antimicrobial agents produced by different species of fly, which
may shed more light on the mechanism of action.59 This
research may yield topical or intravenous therapies with
improved efficacy, without the need for maggot application.
As wound healing evolves and expands as a medical
specialty, it should be possible to encourage more hospital
practitioners to use larval therapy. As most wounds are treated
in the primary care setting, there may be benefit in encouraging
general practitioners to prescribe larval therapy in the home.54
This should prove to be cost effective, decreasing hospital
admissions and the need for surgical intervention.
CONCLUSIONS
From antiquity to the present day, it seems that the unassum-
ing larva is being embraced by twenty first century mainstream
western medicine and has a fixed base in literature and history.
Larval therapy can be used for any infection, but is currently
used for problematic wounds that are often poorly responsive to
conventional treatment. Increased awareness may facilitate its
use in conjunction with established treatments, hopefully in
the setting of prospective clinical trials.
Larval therapy benefits patients through rapid wound
debridement, elimination of infection and odour, and possible
prevention of amputation. It may decrease overall antibiotic
use, prevent hospital admission, and decrease outpatient visits.
From a pragmatic point of view, larval therapy is relatively
cheap and may save money by those factors mentioned above
and by reducing bed occupancy. As antibiotic resistance
becomes increasingly prevalent,60 61 this ancient remedy may
once again be at the forefront of human survival.
MULTIPLE CHOICE QUESTIONS (TRUE (T)/FALSE(F);
ANSWERS AFTER THE REFERENCES)
1. With regard to the application of larval therapy:
(A) Larval therapy cannot be used for wounds containing
methicillin-resistant S aureus
(B) Larval therapy is commonly applied as a first line
treatment for venous ulcers
(C) Patients are averse to larval therapy as it increases odour
(D) Larval therapy may be used in patients undergoing
chemotherapy
(E) Some antibiotics kill the larvae
2. With regard to the mechanism of action of larvae:
(A) The exact mechanisms are precisely mapped
(B) Ammonia is produced by the larvae
(C) Mouth hooks allow the larvae to hold their exact position
once placed
(D) Enzymes produced by the larvae break down healthy
tissue
(E) Larvae ingest microorganisms which are destroyed in
their gut
3. To apply larval therapy:
(A) The maggots are placed in your hand during transfer
(B) A net cage is created to place the larvae in the wound
(C) A silicone dressing is used to hold the net in place
(D) The larvae must be in contact with the surrounding skin
for proper debridement
(E) A non-woven swab is used to draw away moisture
4. Problems with larval therapy include:
(A) Public acceptance
(B) The therapy is usually painful
(C) It is very time consuming for nursing staff to look after
(D) A lack of randomised control trials
(E) The cost
5. Larval therapy may be used to treat:
(A) Any superficial infection
(B) Certain types of fungating cancers
(C) Infected burns
(D) Osteomyelitis
(E) Abdominal infections with exposed bowel
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ANSWERS
1. (A) F, (B) F, (C) F, (D) T, (E) F;
2. (A) F, (B) T, (C) F, (D) F, (E) T;
3. (A) F, (B) T, (C) F, (D) F, (E) T;
4. (A) T, (B) F, (C) F, (D) T, (E) F;
5. (A) T, (B) T, (C) T, (D) T, (E) F.
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